RT Journal Article
SR Electronic
T1 Impact of biologic therapy in severe asthma with nasal polyps
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3739
DO 10.1183/13993003.congress-2021.PA3739
VO 58
IS suppl 65
A1 Tinoco, Eduarda M.
A1 Gigante, Ana R.
A1 Fernandes, Ana L.
A1 Cabrita, Bruno
A1 Santa, Cátia
A1 Sucena, Inês
A1 Silva, Margarida
A1 Martins, Sara
A1 Machado, Daniela
A1 Franco, Inês
A1 Ladeira, Inês
A1 Pascoal, Ivone
A1 Lima, Ricardo
YR 2021
UL https://publications.ersnet.org//content/58/suppl_65/PA3739.abstract
AB Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is responsible for an increased overall disease burden among patients with asthma. Biologics are an establish therapy for severe asthma and its efficacy in patients with co-existent CRSwNP has been a subject of interest.Aim: To compare the impact of biologic therapy in severe asthma patients with and without CRSwNP.Materials and methods: Multicenter retrospective study of severe asthma patients under biologic therapy in 2020. We compared 20 patients with CRSwNP with a randomized sample of 34 patients without CRSwNP.Results: 54 severe asthma patients were included and both groups were homogeneous concerning sex, age, BMI, smoking habits and BMI. CRSwNP20.0(37.0)Without CRSwNP34.0(63.0)p-value ΔT/0T/6-12MT/0T/6-12MACTSNOT-22Low dose OCS regimeShort-term use OCS+Asthma exacerbation+10.5[9.0–12.5]70.3±14.47.0(35.0)3.5[2.0–7.0]4.0[2.0–12.0]22.0[20.0–22.5]24.1±10.93.0(15.0)0.0[0.0–0.0]1.0[0.0–1.0]9.0[7.0–11.8]-11.0(32.4)2.0[2.0–4.0]3.0[2.0–5.0]21.0[19.8–24.0]-5.0(14.7)0.0[0.0–1.5]1.0[0.0–2.0]0.419-0.8220.031*0.078Eosinophilia585.0[300.0-135.0]100.0[97.5–232.5]350.0[140.0–740.0]115.0[65.0–280.0]0.139Pre-bronchodilator FEV1 (%)66.9±24,975.2±17,458.6±15.867.1±15.70.983Data present as n(%), mean±standard deviation or median[range]. T0–beginning of therapy; T/6-12M–6-12 months after; Δ–variation between T/6-12M and T0. +previous year; *p < 0.05Discussion: Before treatment patients with CRSwNP had more asthma exacerbations with more short-term use of OCS;after biologics, they experience a greater reduction in the total number of prescribed OCS courses acquiring an exacerbation pattern similar to those under biologics without CRSwNP.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3739.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).